*.- Doble Combinación .
*.- Triple Combinación .
*.- Cuadruple Combinación .
A destacar la Cuadruple Combinación iniciada el pasado 9 de Agosto :
PharmaMar starts a quadruple combination study with Aplidin for the treatment of multiple myeloma .
* Aplidin® is an ideal compound for combining with other therapies given its absence of Hematological toxicity, excellent safety profile along with its already demonstrated tolerance in triple combination .
* The success of this study will place Aplidin® at the front line of multiple myeloma treatment .
* The trial looks at combating multiple myeloma with the synergies of different mechanisms of action, increasing the possibility of success.
